This review describes and discusses the different assays used to measure the effectiveness
of the novel therapeutic agent, emicizumab, as well as monitor factor VIII activity in patients …

Hemophilia A is an X-linked recessive bleeding disorder characterized by absent or
ineffective coagulation factor VIII, a condition that could result in a severe and potentially life …

Background Accurate measurement of emicizumab in the presence of factor (F) VIII is
required in patients with severe hemophilia A treated with emicizumab, as well as additional …

This chapter will describe a method for measuring endogenous and infused Factor VIII
(FVIII) in patients on emicizumab therapy (Hemlibra, Genetec, Inc). Emicizumab is a …

Introduction The factor VIII mimetic emicizumab (Hemlibra, Hoffman‐la Roche, Basel,
Switzerland) has a novel mode of action that affects the laboratory monitoring of patients …

Background Emicizumab is a humanized bispecific monoclonal antibody that bridges
activated factor IX (FIXa) and factor X (FX) to mimic the function of factor VIII (FVIII). It …

Emicizumab is a humanized monoclonal antibody which binds to the coagulation factors (F)
IX/IXa and X. By connecting FIXa and FX, Emicizumab mimics the cofactor function of FVIIIa …

Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the
function of activated FVIII deficient in haemophilia A, represents a major therapeutic …

Abstract Emicizumab (ACE910), a recombinant humanized bispecific monoclonal antibody,
provides factor VIII (FVIII) cofactor bridging function to restore hemostasis in people with …

Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of
coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is …